Updates from The Motley Fool

Latest updates on ImmunoGen from Fool.com.

Stock Performance

IMGN vs. S&P 500 | 2 Year Performance
IMGN 1-Day Stock Chart
IMGN 5-Day Stock Chart
IMGN 1-Month Stock Chart
IMGN 3-Month Stock Chart
IMGN 6-Month Stock Chart
IMGN 1-Year Stock Chart
IMGN 2-Year Stock Chart
IMGN 5-Year Stock Chart
View Interactive IMGN Charts
Sponsored by

Key Data Points

Primary metrics and data points about ImmunoGen.
Current Price: $6.85
Prev Close: $8.45
Open: $7.07
Bid: $6.83
Ask: $7.08
Day's Range: $6.59 - $7.25
52wk Range: $6.59 - $19.43
Volume: 5,302,751
Avg Vol 894,846
Market Cap: $595.84M
P/E (ttm): -5.87
EPS (ttm): -$1.44
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about ImmunoGen.
CAPS Rating 4 out of 5
325 Outperform
22 Underperform
CAPS All Stars
59 Outperform
3 Underperform

How do you think ImmunoGen will perform against the market?

You pick for ImmunoGen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Dan Junius, CEO

71% Approve

Based on 15 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for ImmunoGen.

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers